Article Text

Download PDFPDF

4CPS-177 Long-acting intramuscular antiretrovirals: what real-world data do we have?
  1. S Esteban1,
  2. I Canamares-Orbis1,
  3. C Esteban-Alba1,
  4. N Font-Tarres1,
  5. L Pedraza-Nieto1,
  6. S Prieto-Roman1,
  7. J Troya-Garcia2,
  8. P Ryan-Murua2,
  9. G Cuevas-Tascon2,
  10. M Matarranz-Del Amo2,
  11. I Escobar-Garcia1,
  12. S Rodriguez-Perut2
  1. 1Hospital Universitario Infanta Leonor, Pharmacy, Madrid, Spain
  2. 2Hospital Universitario Infanta Leonor, Internal Medicine, Madrid, Spain


Background and Importance The new intramuscular antiretroviral treatments (IM-ART), cabotegravir-rilpivirine, have represented a breakthrough in reducing stigma and improving adherence among HIV patients. However, it is necessary to understand how their real-world use impacts patient outcomes.

Aim and Objectives To assess the effectiveness and safety of IM-ART in real-world settings and investigate their impact on analytical parameters.

Material and Methods A retrospective observational study conducted from January to September 2023, including all patients treated with LA-ART with at least three doses. Demographic data (age, gender), treatment-related information (previous ART and presence of resistance mutations (RM)), clinical data (LDL-cholesterol, HDL-cholesterol, creatinine, GOT, GPT, alkaline phosphatase, GGT, total bilirubin, calcium, and phosphorus before and after IM-ART), and effectiveness data (HIV-RNA copies (CV), CD4 count, and CD4/CD8 ratio before and after starting IM-ART) were collected. Adverse events (AE) and pain assessed on the Visual Analog Scale (VAS) during the first two administrations were recorded. Paired Student’s t-test and Wilcoxon signed-rank test were used for statistical analysis of differences between pre- and post-LA-ART variables, depending on the distribution. Statistical analysis was performed using Stata/IC16.1 software.

Results Sixty-six patients (93.9% men) were analysed. Median age: 42 years (IQR:38–46). 50,0% were receiving triple therapy before the switch, and 27.6% had at least one RM, which did not affect IM-ART. Three patients had CV>30 copies/mL before starting LA-ART. All patients included maintained CV<30 copies/mL during the study period. Statistically significant differences were observed in LDL-cholesterol (p=0.0193) and CD4 (p=0.0035) between pre- and post-IM-ART values.

All patients experienced at least one AE, with injection site reactions being the most frequent (98.5%). The observed AEs included: general malaise (36.7%), asthenia (13.6%), fever (12.1%), diarrhoea (9.1%), headache (7.6%), sleep disturbances (6.1%), nausea (3.0%), and others (4.5%). One patient discontinued IM-ART due to AE.

Differences in pain assessed on the VAS were observed between rilpivirine vs cabotegravir administration [0.9 (95% CI: 0.3–1.5; p=0.0029)] and between the second vs first administration: rilpivirine [1.6 (95% CI: 0.5–2.7; p=0.0042)]; cabotegravir [1.6 (95% CI: 0.6–2.6; p=0.0032)].

Conclusion and Relevance LA-ART has demonstrated effectiveness and acceptable safety in real-world data, consistent with the results of the ATLAS and FLAIR studies. Longer-term studies are needed to evaluate the evolution of CD4 counts, LDL levels and pain.

Conflict of Interest No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.